Prevalence of hepatitis
Hepatitis poses a significant public health challenge in Pakistan, with Hepatitis B and C being the most prevalent strains, leading to substantial morbidity and mortality. Pakistan ranks among the top ten countries heavily burdened by these infections — with an estimated 10-15% of the population, around 15-20 million people, infected.
The prevalence rate of Hepatitis C alone is 4.8%. Major causes of transmission include unsafe medical practices, such as the use of non-sterilised syringes and unscreened blood transfusions from infected donors. Pakistan has one of the highest rates of therapeutic injections globally, with around 80 million administered annually — averaging 4.5 per person.
The reuse of these equipment without sterilisation has further fuelled the spread of blood-borne infections. Additionally, poor awareness of hygiene practices contributes to the transmission of Hepatitis A and E.
To combat this crisis, the government and healthcare professionals must enforce strict sterilisation protocols and ensure all blood products are thoroughly screened. Public awareness campaigns about hepatitis transmission and prevention are essential.
Investments should also focus on providing clean water and proper waste disposal systems. Universal access to Hepatitis B vaccinations must be guaranteed. This ongoing neglect of basic healthcare rights is an injustice to the people, and those entrusted with saving lives must not become the cause of their end.
Sana Gulzar
Karachi
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Recorder
4 days ago
- Business Recorder
Pakistan's vaccine independence: a national imperative
Pakistan stands at a critical crossroads in public health policy. With seven million births annually and a population growth rate of 2.55%, our nation faces an unprecedented challenge in vaccine security that demands immediate and decisive action. The looming withdrawal of GAVI support by 2031 presents not just a crisis, but an opportunity to transform Pakistan into a self-reliant pharmaceutical powerhouse. The stark reality we face The numbers paint a sobering picture of our current vulnerability. Pakistan's complete dependency on donated and discounted vaccine supplies, supported by GAVI, UNICEF, and WHO to the tune of PKR 26 billion annually, masks a deeper structural weakness. When GAVI's support ends in 2031, the financial burden will balloon to PKR 100 billion annually as nearly four times our current federal health budget of PKR 27 billion. This dependency is not merely financial; it represents a fundamental threat to national health security. This isn't just underdevelopment—it's a systematic surrender of national health autonomy. Today, Pakistan produces virtually no antigens for the Expanded Programme on Immunization (EPI) vaccines domestically. We lack essential seed banks, have minimal university-based vaccine development programs, and operate with regulatory guidelines that are inadequate for sophisticated vaccine manufacturing. Our clinical trial expertise remains severely limited, creating bottlenecks in bringing locally developed vaccines to market. The contrast with global pharmaceutical leaders is stark. While universities worldwide have been the birthplace of revolutionary vaccines-from the Hepatitis B vaccine developed at UC San Francisco to the Oxford-AstraZeneca Covid-19 vaccine-Pakistan's academic institutions remain largely disconnected from commercial vaccine production. Learning from global success stories International experience offers valuable lessons. India transformed itself into the 'pharmacy of the world' through strategic government support for generic manufacturing and robust regulatory frameworks. Singapore built a biomedical hub through integrated research, manufacturing, and regulatory excellence that attracted billions in global pharmaceutical investment. South Korea's government-industry partnerships created world-class biopharmaceutical capabilities. These success stories share common elements: sustained government commitment, strategic investment in infrastructure, regulatory excellence, and comprehensive talent development programs. Most importantly, they demonstrate that with the right approach, developing nations can achieve pharmaceutical self-sufficiency and even become global exporters. The Triple Helix solution The path forward requires unprecedented coordination between government, academia, and industry -what experts call the 'Triple Helix' approach. Each sector must play a distinct yet interconnected role in building national vaccine capacity. Government leadership is essential in creating policy frameworks that incentivize domestic production while providing funding for university research. Strategic assignments to national research institutions like the National Institute of Health, Centre of Excellence in Molecular Biology (CEMB), National Institute for Biotechnology and Genetic Engineering (NIBGE), International Centre for Chemical and Biological sciences (ICCBS), Karachi University, Department of Biotechnology, Dow University of Health Sciences (DUHS), etc., can accelerate vaccine development and establish crucial seed banks. Most critically, the government must develop a comprehensive national health security strategy that positions vaccine self-sufficiency as a matter of national defense. The regulatory transformation cannot be understated. Pakistan's Drug Regulatory Authority must achieve WHO Level 3 qualification and create 'regulatory sandboxes — collaborative environments where university researchers, industry partners, and regulatory experts jointly develop guidelines for the 13 critical EPI vaccine antigens. Fast-track approval pathways and clear regulatory roadmaps will accelerate the journey from laboratory research to commercial production. Formation of sandboxes by bringing together leaders of the University, Regulatory and Industry. Universities must step up as innovation engines. Institutions with BSL-III laboratories should lead development of live attenuated vaccines, while biotechnology departments focus on recombinant vaccine technologies. Specialized vaccine research centers, industry-relevant curricula, and technology transfer offices will bridge the gap between academic discovery and commercial application. State-of-the-art pilot manufacturing facilities will provide proof-of-concept capabilities essential for scaling innovations. Industry brings manufacturing excellence and market expertise to the equation. Private sector partners can transform academic research into GMP-compliant commercial production, establish robust supply chains for raw materials, and navigate complex regulatory approvals. Their distribution networks and market access capabilities will ensure that domestically produced vaccines reach every corner of Pakistan. Leading companies in Pakistan already in the field of Biopharmaceutical manufacturing must be involved in the development process. A realistic implementation roadmap Success requires a phased approach spanning six years. The foundation phase (Years 1-2) must establish policy frameworks and coordination mechanisms while launching capacity-building programmes. Infrastructure development (Years 2-4) involves scaling laboratory manufacturing capabilities, establishing vaccine testing facilities, and launching pilot production programs. The scale-up phase (Years 4-6) transitions to commercial production of EPI vaccines, regulatory approvals, and distribution network establishment. Finally, the optimization phase (Year 6+) expands manufacturing capabilities, develops advanced biologics production, and positions Pakistan as a regional pharmaceutical hub. Financial innovation will be crucial. Blended financing models combining public funding, private investment, and support from institutions like the Islamic Development Bank can mobilise the substantial capital required for drug substance manufacturing facilities. The initial investment may be significant, but the long-term savings and export potential far outweigh the costs. The economic and strategic imperative The benefits extend far beyond health security. A robust domestic vaccine industry could create over 5,000 jobs and reduce import dependency by 50 percent. More importantly, it would establish Pakistan as a regional pharmaceutical hub with significant export potential to neighboring countries and the broader Islamic world. The Covid-19 pandemic demonstrated the critical importance of pharmaceutical self-reliance. Nations with domestic production capabilities could respond rapidly to their populations' needs, while others waited months for external supplies. This lesson cannot be ignored as we face an uncertain global health landscape. The time for action is now Pakistan's demographic dividend — with 65 percent of the population under 30 — represents an unprecedented opportunity to build a knowledge-based pharmaceutical sector. However, this window will not remain open indefinitely. The GAVI deadline of 2031 provides a clear timeline for action, but preparation must begin immediately. The success of this transformation depends on political will, sustained investment, and most importantly, recognition that vaccine self-sufficiency is not a luxury but a national security imperative. Countries that fail to develop domestic pharmaceutical capabilities will remain perpetually vulnerable to supply disruptions, price volatility, and foreign policy pressures. A call to national action The establishment of National and Provincial Coordination Committees bringing together leaders from academia, industry, and regulatory agencies represents the essential first step. This must be followed by a comprehensive assessment of current capabilities, development of a detailed national vaccine strategy, and launch of pilot programmes for immediate impact. Pakistan has the intellectual capital, institutional foundation and market potential to achieve vaccine independence. What we need now is the collective will to transform this potential into reality. The health and prosperity of future generations depend on the decisions we make today. The choice is clear: remain dependent on the goodwill of international donors or invest in building a self-reliant pharmaceutical sector that serves not only Pakistan's needs but positions the nation as a leader in global health innovation. The Triple Helix approach offers a proven pathway to pharmaceutical independence-we must have the courage to take it. Copyright Business Recorder, 2025
Express Tribune
28-04-2025
- Express Tribune
Experts urge launch of adult vaccination programme
Medical experts said that just like children, adults also need vaccinations to prevent treatable diseases and reduce mortality yet there is no vaccination programme available in Pakistan for adults. Associate Professor at Aga Khan University Hospital Dr Iffat Khanam said that during the COVID-19 pandemic, vaccination reduced the severity of the disease. However, there is still a lack of healthcare facilities and awareness about adult vaccination. She said that World Immunization Week is being observed, but while there is a focus on childhood vaccinations, adult vaccinations are being neglected. There are many infections for which vaccines are available, but in Pakistan, there are no centres for adult vaccinations, nor is there any specific programme in place for adults. The pneumococcal vaccine is given to prevent pneumonia, which is necessary for persons with respiratory or kidney disease, diabetes, or those over 60 years of age. Influenza is a viral infection that peaks in September and October, and getting a flu vaccine can provide protection. Hepatitis B is common in Pakistan, which not only causes liver damage but also increases the risk of liver cancer. However, getting vaccinated against Hepatitis B can provide protection.
Express Tribune
18-04-2025
- Express Tribune
Pakistan, Egypt agree to boost health sector cooperation
Listen to article Pakistan and Egypt have agreed to strengthen bilateral cooperation in the health sector, with a special focus on eliminating Hepatitis C, following a high-level meeting between Federal Health Minister Mustafa Kamal and the Egyptian Ambassador. According to a statement from the Ministry of Health, the two sides discussed technical collaboration and initiatives to develop the medical field in Pakistan. A delegation of Egyptian health experts is expected to visit Pakistan soon to assist in Hepatitis C eradication efforts. Health Minister Mustafa Kamal praised Egypt's notable success in eliminating Hepatitis C and briefed the ambassador on Pakistan's progress under the Prime Minister's Hepatitis C Elimination Program. 'The Egyptian model of tackling Hepatitis C is commendable,' Kamal said. 'We are committed to benefiting from Egypt's experience in this area and look forward to practical collaboration.' The Egyptian ambassador lauded Pakistan's decision to adopt aspects of Egypt's approach and reaffirmed Cairo's commitment to supporting Islamabad through technical assistance, training programs, and awareness campaigns. The ambassador also confirmed that Egypt would soon send a team of health experts to Pakistan to begin working on joint strategies. Minister Kamal welcomed the move, stating that Pakistan would make full use of the visiting delegation's expertise and experience in public health interventions. The development marks a significant step in Pakistan's efforts to fight viral diseases and improve healthcare services through international cooperation. This partnership reflects a growing trend of health diplomacy in the region, as countries seek to share knowledge, models, and resources to address common challenges in public health.
